AI Insight
Researchers found that blocking the glycine transporter SLC6A20 restored brain signaling and improved social, communication, and repetitive behaviors in mouse models of autism. The treatment showed effectiveness in both young and adult mice, as well as in human brain organoids. These results challenge the assumption that therapeutic interventions for autism must occur early in development to be effective.
Why it matters
This research suggests a potential new therapeutic target for autism spectrum disorder that may remain viable into adulthood. If translatable to humans, this approach could expand treatment options beyond early childhood interventions and benefit individuals across the lifespan.
Understand the Science
Blocking the glycine transporter SLC6A20 restored important brain signaling and improved social, communication, and repetitive behaviors in autism-related mouse models. The treatment also worked in human brain organoids and showed lasting effects in adult mice, suggesting the brain may remain more treatable later in life than previously thought.
Source: New autism therapy shows surprising benefits even in adult mice